{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:49:52Z","timestamp":1791319792483,"version":"4.3.1"},"reference-count":110,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>(1) Background: Tumors of the peritoneal serosa are called peritoneal carcinosis. Their origin may be primary by primitive involvement of the peritoneum (peritoneal pseudomyxoma, peritoneal mesothelioma, etc.). This damage to the peritoneum can also be a consequence of the dissipation of cancers\u2014in particular, digestive (stomach, pancreas, colorectal, appendix) and gynecological (ovaries) ones in the form of metastases. The aim of the treatment is a maximal reduction of the macroscopic disease called \u201ccytoreduction\u201d in combination with hyperthermic intra-abdominal chemotherapy to treat residual microscopic lesions. (2) Methods: In this narrative review, we fundamentally synthetize the evolution of this process over time and its impact on clinical applications. (3) Results: Over the last past decade, different evolutions concerning both delivery modes and conditions concerning hyperthermic intra-abdominal chemotherapy have been realized. (4) Conclusion: The final objective of these evolutions is the improvement of the global and recurrence-free survival of primary and secondary malignant peritoneal pathologies. However, more large randomized controlled trials are needed to demonstrate the efficacy of such treatments with the help of molecular biology and genetics.<\/jats:p>","DOI":"10.3390\/biology10030225","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T11:38:58Z","timestamp":1615808338000},"page":"225","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2125-0503","authenticated-orcid":false,"given":"Niki","family":"Christou","sequence":"first","affiliation":[{"name":"Service de Chirurgie Digestive, Endocrinienne et G\u00e9n\u00e9rale, CHU de Limoges, Avenue Martin Luther King, 87042 Limoges CEDEX, France"},{"name":"Department of Visceral Surgery, Geneva University Hospitals and Medical School, Geneva, Rue Gabrielle Perret-Gentil 4, 1205 Geneva, Switzerland"},{"name":"Laboratoire EA 3842, CAPtuR, Contr\u00f4le de l\u2019Activation Cellulaire, Progression Tumorale et R\u00e9sistance Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5260-535X","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Auger","sequence":"additional","affiliation":[{"name":"Laboratoire EA 3842, CAPtuR, Contr\u00f4le de l\u2019Activation Cellulaire, Progression Tumorale et R\u00e9sistance Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Battu","sequence":"additional","affiliation":[{"name":"Laboratoire EA 3842, CAPtuR, Contr\u00f4le de l\u2019Activation Cellulaire, Progression Tumorale et R\u00e9sistance Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0382-4948","authenticated-orcid":false,"given":"Fabrice","family":"Lallou\u00e9","sequence":"additional","affiliation":[{"name":"Laboratoire EA 3842, CAPtuR, Contr\u00f4le de l\u2019Activation Cellulaire, Progression Tumorale et R\u00e9sistance Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Odile","family":"Jauberteau-Marchan","sequence":"additional","affiliation":[{"name":"Laboratoire EA 3842, CAPtuR, Contr\u00f4le de l\u2019Activation Cellulaire, Progression Tumorale et R\u00e9sistance Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2489-8893","authenticated-orcid":false,"given":"C\u00e9line","family":"Hervieu","sequence":"additional","affiliation":[{"name":"Laboratoire EA 3842, CAPtuR, Contr\u00f4le de l\u2019Activation Cellulaire, Progression Tumorale et R\u00e9sistance Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8162-4856","authenticated-orcid":false,"given":"Mireille","family":"Verdier","sequence":"additional","affiliation":[{"name":"Laboratoire EA 3842, CAPtuR, Contr\u00f4le de l\u2019Activation Cellulaire, Progression Tumorale et R\u00e9sistance Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Mathonnet","sequence":"additional","affiliation":[{"name":"Service de Chirurgie Digestive, Endocrinienne et G\u00e9n\u00e9rale, CHU de Limoges, Avenue Martin Luther King, 87042 Limoges CEDEX, France"},{"name":"Laboratoire EA 3842, CAPtuR, Contr\u00f4le de l\u2019Activation Cellulaire, Progression Tumorale et R\u00e9sistance Th\u00e9rapeutique, Facult\u00e9 de M\u00e9decine, 2 rue du Docteur Marcland, 87025 Limoges CEDEX, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1158\/1055-9965.EPI-08-0771","article-title":"Incidence of Ovarian, Peritoneal, and Fallopian Tube Carcinomas in the United States, 1995\u20132004","volume":"18","author":"Goodman","year":"2009","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jso.21167","article-title":"Malignant abdominal mesothelioma: Defining the role of surgery","volume":"99","author":"Cheung","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Babaier, A., and Ghatage, P. (2020). Mucinous Cancer of the Ovary: Overview and Current Status. Diagnostics, 10.","DOI":"10.3390\/diagnostics10010052"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br. J. Surg."},{"key":"ref_5","first-page":"2131","article-title":"Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer","volume":"14","author":"Ikeguchi","year":"1994","journal-title":"Anticancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O","article-title":"Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study","volume":"88","author":"Sadeghi","year":"2000","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1369\/0022155417742897","article-title":"Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review","volume":"66","author":"Nieuwland","year":"2018","journal-title":"J. Histochem. Cytochem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0035-1564433","article-title":"Management of Appendix Cancer","volume":"28","author":"Kelly","year":"2015","journal-title":"Clin. Colon Rectal Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4251\/wjgo.v2.i1.12","article-title":"Pathophysiology and biology of peritoneal carcinomatosis","volume":"2","author":"Kusamura","year":"2010","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","article-title":"The histophysiology and pathophysiology of the peritoneum","volume":"49","author":"Nieuwland","year":"2017","journal-title":"Tissue Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.neo.2019.08.006","article-title":"Fibrin Deposit on the Peritoneal Surface Serves as a Niche for Cancer Expansion in Carcinomatosis Patients","volume":"21","author":"Shahid","year":"2019","journal-title":"Neoplasia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00018-017-2663-1","article-title":"The peritoneal \u201csoil\u201d for a cancerous \u201cseed\u201d: A comprehensive review of the pathogenesis of intraperitoneal cancer metastases","volume":"75","author":"Uruski","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12032-018-1122-7","article-title":"Role of matrix metalloproteinases in tumour invasion: Immunohistochemistry of peritoneum from peritoneal carcinomatosis","volume":"35","author":"Falk","year":"2018","journal-title":"Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41467-018-04695-7","article-title":"Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface","volume":"9","author":"Tang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<254::AID-SSU10>3.0.CO;2-U","article-title":"Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis","volume":"14","author":"Sugarbaker","year":"1998","journal-title":"Semin. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2014184","DOI":"10.1001\/jamanetworkopen.2020.14184","article-title":"Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?","volume":"3","author":"Alter","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/02656736.2017.1291999","article-title":"Drugs, doses, and durations of intraperitoneal chemotherapy: Standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma","volume":"33","author":"Lemoine","year":"2017","journal-title":"Int. J. Hyperth."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s002800050721","article-title":"Hyperthermic intraperitoneal doxorubicin: Pharmacokinetics, metabolism, and tissue distribution in a rat model","volume":"41","author":"Jacquet","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.21873\/anticanres.14700","article-title":"Hyperthermia During Intraperitoneal Chemotherapy with Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit?","volume":"40","author":"Bree","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00280-003-0626-8","article-title":"Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics","volume":"52","author":"Stuart","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00000441-198610000-00004","article-title":"The Importance of the Abdominal Viscera to Peritoneal Transport During Peritoneal Dialysis in the Dog","volume":"292","author":"Rubin","year":"1986","journal-title":"Am. J. Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/089686080302300605","article-title":"Is the peritoneum a significant transport barrier in peritoneal dialysis?","volume":"23","author":"Flessner","year":"2003","journal-title":"Perit. Dial. Int. J. Int. Soc. Perit. Dial."},{"key":"ref_24","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Speyer, J.L., and Myers, C.E. (1980). The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Cancer Chemo-and Immunopharmacology, Springer.","DOI":"10.1007\/978-3-642-81488-4_31"},{"key":"ref_26","first-page":"181","article-title":"A bacteriologically safe peritoneal access device","volume":"14","author":"Tenckhoff","year":"1968","journal-title":"Trans. Am. Soc. Artif. Int. Org."},{"key":"ref_27","unstructured":"Sugarbaker, P.H. (2005). Technical Handbook for the Integration of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy into the Surgical Management of Gastrointestinal and Gynecologic Malignancy, Laudann Company. [4th ed.]."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4251\/wjgo.v12.i7.756","article-title":"Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative","volume":"12","author":"Leiting","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","article-title":"Intraperitoneal therapy for peritoneal tumors: Biophysics and clinical evidence","volume":"7","author":"Ceelen","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/1097-0142(197706)39:6<2637::AID-CNCR2820390650>3.0.CO;2-S","article-title":"Effect of hyperthermia on malignant cells in vivo: A review and a hypothesis","volume":"39","author":"Overgaard","year":"1977","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1055-3207(03)00029-2","article-title":"Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents","volume":"12","author":"Sticca","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/bjs.1800780119","article-title":"Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat","volume":"78","author":"Shimizu","year":"1991","journal-title":"BJS Br. J. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: Rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/00001813-199607000-00016","article-title":"Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration","volume":"7","author":"Jacquet","year":"1996","journal-title":"Anticancer. Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1515\/pp-2017-0015","article-title":"Experimental pharmacokinetics evaluation of chemotherapy delivery by PIPAC for colon cancer: First evidence for efficacy","volume":"2","author":"Eveno","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1515\/pp-2016-0023","article-title":"Morphology of the peritoneal cavity and pathophysiological consequences","volume":"1","author":"Solass","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00464-011-1964-y","article-title":"Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: Proof of concept","volume":"26","author":"Solass","year":"2012","journal-title":"Surg. Endosc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/bjs5.50257","article-title":"Pressurized intraperitoneal aerosol chemotherapy: A review of the introduction of a new surgical technology using the IDEAL framework","volume":"4","author":"Tate","year":"2020","journal-title":"BJS Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy","volume":"21","author":"Solass","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1245\/s10434-013-3039-x","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Occupational Health and Safety Aspects","volume":"20","author":"Zieren","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1245\/s10434-012-2840-2","article-title":"Renal and Hepatic Toxicities After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)","volume":"20","author":"Blanco","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.ejso.2019.06.018","article-title":"Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis","volume":"45","author":"Willaert","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1245\/s10434-020-08743-9","article-title":"Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial","volume":"28","author":"Lurvink","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_44","first-page":"385","article-title":"From palliation to cure: PIPAC for peritoneal malignancies","volume":"110","author":"Abatini","year":"2019","journal-title":"Minerva Med."},{"key":"ref_45","unstructured":"(2021, February 23). Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02735928."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1245\/s10434-016-5148-9","article-title":"Efficacy of Early Postoperative Intraperitoneal Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer: A Case\u2013Control Study from a Single Center","volume":"23","author":"Park","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_47","unstructured":"(2020, October 18). Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. Available online: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa052985."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2013.12.028","article-title":"Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: A case series","volume":"132","author":"Fagotti","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","article-title":"Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients","volume":"100","author":"Valle","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/02656736.2016.1152514","article-title":"Prophylactic hyperthermic intraperitoneal chemotherapy in patients with epithelial appendiceal neoplasms","volume":"32","author":"Tuvin","year":"2016","journal-title":"Int. J. Hyperth. Off. J. Eur. Soc. Hyperthermic"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: Towards personalized chemotherapy?","volume":"11","author":"Pasquier","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S1055-3207(03)00035-8","article-title":"Effective therapy for peritoneal dissemination in gastric cancer","volume":"12","author":"Yonemura","year":"2003","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","author":"Ishigami","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_54","first-page":"40","article-title":"Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer","volume":"22","author":"Zylberberg","year":"2001","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1245\/s10434-016-5487-6","article-title":"Effects of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy and Neoadjuvant Intraperitoneal\/Systemic Chemotherapy on Peritoneal Metastases from Gastric Cancer","volume":"24","author":"Yonemura","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1245\/s10434-011-1770-8","article-title":"Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients with Peritoneal Dissemination","volume":"18","author":"Fujiwara","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejso.2006.03.007","article-title":"Neoadjuvant treatment of gastric cancer with peritoneal dissemination","volume":"32","author":"Yonemura","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00280-011-1646-4","article-title":"Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: A prospective pilot study","volume":"68","author":"Rubio","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Prabhu, A., Brandl, A., Wakama, S., Sako, S., Ishibashi, H., Mizumoto, A., Takao, N., Noguchi, K., Motoi, S., and Ichinose, M. (2020). Neoadjuvant Intraperitoneal Chemotherapy in Patients with Pseudomyxoma Peritonei-A Novel Treatment Approach. Cancers, 12.","DOI":"10.3390\/cancers12082212"},{"key":"ref_60","first-page":"26","article-title":"A new bidirectional intraperitoneal and systemic induction chemotherapy (BISIC) for the peritoneal metastasis from gastric cancer in neoadjuvant setting","volume":"1","author":"Yonemura","year":"2014","journal-title":"Integr. Cancer Sci. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jso.21324","article-title":"Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery","volume":"100","author":"Yonemura","year":"2009","journal-title":"J. Surg. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/SLA.0b013e3181b0c80e","article-title":"Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma","volume":"250","author":"Kuramoto","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3892\/etm.2014.1599","article-title":"Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer","volume":"7","author":"Cui","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ejso.2018.10.086","article-title":"A UNICANCER phase III trial of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Carcinomatosis. PRODIGE 7","volume":"45","author":"Quenet","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1000 Patients","volume":"218","author":"Levine","year":"2014","journal-title":"J. Am. Coll. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/annonc\/mdl428","article-title":"A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma","volume":"18","author":"Yan","year":"2007","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2019.37.4_suppl.377","article-title":"Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?","volume":"37","author":"Gamboa","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_70","first-page":"1","article-title":"Does Intraperitoneal Chemotherapy Increase the Incidence of Anastomotic Leakage after Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis","volume":"2021","author":"Yang","year":"2021","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Soucisse, M.L., Liauw, W., Hicks, G., and Morris, D.L. (2019). Early postoperative intraperitoneal chemotherapy for lower gastrointestinal neoplasms with peritoneal metastasis: A systematic review and critical analysis. Pleura Peritoneum, 4.","DOI":"10.1515\/pp-2019-0007"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00268-001-0067-7","article-title":"Indications for Early Postoperative Intraperitoneal Chemotherapy of Advanced Gastric Cancer: Results of a Prospective Randomized Trial","volume":"25","author":"Yu","year":"2001","journal-title":"World J. Surg."},{"key":"ref_73","first-page":"1104","article-title":"Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer","volume":"64","author":"Yu","year":"1998","journal-title":"Am. Surg."},{"key":"ref_74","first-page":"7291","article-title":"Enhanced antitumor effects by docetaxel\/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer","volume":"10","author":"Fan","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_75","first-page":"5","article-title":"Drug delivery and targeting","volume":"392","author":"Langer","year":"1998","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.7150\/jca.39097","article-title":"Creating nanocrystallized chemotherapy: The differences in pressurized aerosol chemotherapy (PAC) via intracavitary (IAG) and extracavitary aerosol generation (EAG) regarding particle generation, morphology and structure","volume":"11","author":"Khosrawipour","year":"2020","journal-title":"J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"10341","DOI":"10.1038\/s41598-020-67236-7","article-title":"The concept of foam as a drug carrier for intraperitoneal chemotherapy, feasibility, cytotoxicity and characteristics","volume":"10","author":"Schubert","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2017-0010","article-title":"Pharmacological principles of intraperitoneal and bidirectional chemotherapy","volume":"2","author":"Michelakis","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"10572","DOI":"10.1038\/s41598-019-46819-z","article-title":"A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis","volume":"9","author":"Shannon","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"109896","DOI":"10.1016\/j.biopha.2020.109896","article-title":"Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer","volume":"125","author":"Lei","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1080\/15548627.2017.1313945","article-title":"Protein kinase activity of the glycolytic enzyme PGK1 regulates autophagy to promote tumorigenesis","volume":"13","author":"Qian","year":"2017","journal-title":"Autophagy"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ejso.2020.01.018","article-title":"shRNA-mediated inhibition of PhosphoGlycerate Kinase 1 (PGK1) enhances cytotoxicity of intraperitoneal chemotherapy in peritoneal metastasis of gastric origin","volume":"46","author":"Archid","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1038\/s41598-017-09859-x","article-title":"P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting","volume":"7","author":"Gokare","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3389\/fbioe.2020.00378","article-title":"\u03b2-Elemene Reverses the Resistance of p53-Deficient Colorectal Cancer Cells to 5-Fluorouracil by Inducing Pro-death Autophagy and Cyclin D3-Dependent Cycle Arrest","volume":"8","author":"Zhang","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2020.08.002","article-title":"An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers","volume":"154\u2013155","author":"Ando","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/SLA.0000000000002096","article-title":"Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis from Gastric Cancer","volume":"267","author":"Kanda","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/sj.cgt.7700537","article-title":"Oncolytic herpes simplex virus vectors for cancer virotherapy","volume":"9","author":"Varghese","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/cgt.2016.14","article-title":"Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery","volume":"23","author":"Katz","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/cgt.2013.26","article-title":"Inhibitors of C5 complement enhance vaccinia virus oncolysis","volume":"20","author":"Magge","year":"2013","journal-title":"Cancer Gene Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2019.10.034","article-title":"Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: A systematic review","volume":"127","author":"Auer","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1002\/cncr.32496","article-title":"Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer","volume":"125","author":"Vergote","year":"2019","journal-title":"Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","article-title":"Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case-control study on survival in patients with two year follow-up","volume":"127","author":"Fagotti","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13304-018-0600-y","article-title":"Cytoreductive surgery followed by HIPEC repetition for secondary ovarian cancer recurrence","volume":"71","author":"Cianci","year":"2019","journal-title":"Updat. Surg."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.21037\/gs-20-335","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer recurrence: Systematic review and meta-analysis","volume":"9","author":"Cianci","year":"2020","journal-title":"Gland Surg."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/02656736.2018.1503346","article-title":"Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"35","author":"Paris","year":"2018","journal-title":"Int. J. Hyperth. Off. J. Eur. Soc. Hyperthermic"},{"key":"ref_100","unstructured":"Scambia, P.G. (2021, February 22). Surgery Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Versus Surgery Alone in Patients with Platinum-Sensitive First Recurrence of Ovarian Cancer: A Prospective Randomized Multicenter Trial. Report No.: NCT01539785, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01539785."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","article-title":"Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival","volume":"25","author":"Verma","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"Peritoneal Surface Oncology Group International A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process","volume":"40","author":"Carr","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s13304-020-00788-5","article-title":"Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: Result of a single centre study","volume":"72","author":"Corvasce","year":"2020","journal-title":"Updat. Surg."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/bjs.10521","article-title":"Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis","volume":"104","author":"Grass","year":"2017","journal-title":"Br. J. Surg."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2015.02.009","article-title":"Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study","volume":"137","author":"Tempfer","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_106","unstructured":"Khomiakov, V., Ryabov, A., Bolotina, L.V., Utkina, A., Cheremisov, V., Kolobaev, I., Ivanov, A., Chayka, A., and Sobolev, D. (2020, October 20). Bidirectional Chemotherapy in Gastric Cancer (GC) with Peritoneal Carcinomatosis (PC) Combining Intravenous Chemotherapy with Intraperitoneal Chemotherapy with Low-Dose Cisplatin and Doxorubicin Administered as a Pressurized Aerosol: An Open-Label, Phase II Study. Available online: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2017.35.15_suppl.e15532."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Sande, L.V.D., Graversen, M., Hubner, M., Pocard, M., Reymond, M., Vaira, M., Cosyns, S., Willaert, W., and Ceelen, W. (2018). Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (AbraxaneTM) for peritoneal carcinomatosis\u2014A phase I first-in-human study. Pleura Peritoneum, 3.","DOI":"10.1515\/pp-2018-0112"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.ejso.2018.02.014","article-title":"Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study","volume":"44","author":"Nowacki","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"20190010","DOI":"10.1515\/pp-2019-0010","article-title":"MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma","volume":"4","author":"Sgarbura","year":"2019","journal-title":"Pleura Peritoneum"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"20180116","DOI":"10.1515\/pp-2018-0116","article-title":"PIPAC EstoK 01: Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: A randomized and multicenter phase II study","volume":"3","author":"Eveno","year":"2018","journal-title":"Pleura Peritoneum"}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/10\/3\/225\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:36:01Z","timestamp":1760160961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/10\/3\/225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":110,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["biology10030225"],"URL":"https:\/\/doi.org\/10.3390\/biology10030225","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]}}}